Novartis, the Swiss pharmaceutical company, plans to submit 50 new drug applications in China over the next few years, as it projects faster Chinese drug approvals which could see the country overtake Europe to become its second-largest market.
瑞士制药公司诺华(Novartis)计划未来几年在manbetx3.0 提交50份新药申请。该公司预计，manbetx3.0 的药品审批程序提速将使manbetx3.0 取代欧洲成为其第二大市场。
您已阅读7%（316字），剩余93%（3954字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。